SAGE Therapeutics (NASDAQ:SAGE) Upgraded at Svb Leerink

Share on StockTwits

Svb Leerink upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from an underperform rating to a market perform rating in a research report report published on Friday morning, BenzingaRatingsTable reports.

A number of other research firms also recently issued reports on SAGE. Goldman Sachs Group decreased their target price on SAGE Therapeutics from $227.00 to $263.00 in a research report on Thursday. SunTrust Banks cut SAGE Therapeutics from a buy rating to a hold rating and dropped their price target for the company from $210.00 to $70.00 in a research report on Thursday. Wedbush cut their price target on SAGE Therapeutics from $203.00 to $90.00 and set an outperform rating for the company in a research note on Thursday. Morgan Stanley reissued a buy rating and issued a $217.00 price objective on shares of SAGE Therapeutics in a report on Sunday, November 24th. Finally, Cowen reissued a buy rating and issued a $96.00 price objective on shares of SAGE Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $128.81.

SAGE Therapeutics stock opened at $64.46 on Friday. The firm has a 50 day moving average price of $142.30 and a 200-day moving average price of $160.81. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a twelve month low of $56.50 and a twelve month high of $193.56. The company has a market capitalization of $3.34 billion, a P/E ratio of -7.98 and a beta of 2.52.

SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) EPS for the quarter, missing analysts’ consensus estimates of ($3.41) by ($0.07). SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The company had revenue of $3.57 million during the quarter, compared to the consensus estimate of $2.52 million. During the same period last year, the firm posted ($2.63) EPS. The company’s revenue for the quarter was up 35600.0% compared to the same quarter last year. Equities analysts expect that SAGE Therapeutics will post -13.77 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Amundi Pioneer Asset Management Inc. increased its holdings in shares of SAGE Therapeutics by 40.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock worth $21,704,000 after purchasing an additional 39,447 shares during the period. Commonwealth Equity Services LLC boosted its stake in SAGE Therapeutics by 4.5% during the second quarter. Commonwealth Equity Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 77 shares during the period. Creative Planning grew its position in SAGE Therapeutics by 13.0% during the second quarter. Creative Planning now owns 2,563 shares of the biopharmaceutical company’s stock worth $469,000 after buying an additional 294 shares in the last quarter. Janney Capital Management LLC grew its position in SAGE Therapeutics by 18.2% during the second quarter. Janney Capital Management LLC now owns 4,387 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 675 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in SAGE Therapeutics by 5.0% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,557 shares of the biopharmaceutical company’s stock worth $834,000 after acquiring an additional 219 shares during the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.